ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study

This study has been completed.

Sponsored by: National Institute of Environmental Health Sciences (NIEHS)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00342095
  Purpose

Systemic lupus erythematosus (SLE) is severe, chronic, disabling autoimmune disease that significantly affects health status and quality of life. Since the disease occurs most often in young to middle-aged adults, SLE can also affect work and disability. However, there is currently little information on work-related disability from longitudinal, population-based studies of SLE.

Participants were enrolled into the Carolina Lupus Study between February, 1997 and July 1999. We plan to conduct two telephone contacts with patients and one telephone contact with controls in a follow-up study to be conducted in 2001. The first patient contact will follow an introductory letter that describes the follow-up study. This letter provides participants the opportunity (via a toll-free phone number) to decline further contact about this study. The first patient contact will be a short (5 minute) interview in which we determine their current source of lupus-related medical care, timing of next expected visit, and update contact information. The second contact will involve a 60-minute telephone interview covering medical care utilization, current health status (including a patient-administered measure of lupus activity), work and disability issues, psychosocial attributes (e.g. helplessness, social support, daily stressors including race-related issues), and changes in exposures since the initial interview. We will attempt to schedule the patients' interviews within 3 months before or after the patient sees his or her own physician for SLE-related evaluation or treatment. A short (15 minutes or less) telephone interview will be conducted with controls focusing on current health, work status, and daily stresso.

Ddisease damage will be assessed using the System Lupus international Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index, a standardized and validated instrument that is completed by the patient's physician.

We will seek death certificates for patients and controls who have died in order to obtain cause of death information. Next-of-kin information from death certificates will not be used.

This study will allow up to determine the feasibility of obtaining reliable data on disease damage from more than 50 physicians involved in the treatment of patients in the Carolina Lupus Study. This developmental work is a necessary foundation for any additional follow-up studies of the Carolina Lupus Study cohort. We will also be able to examine associations with disability in patients and in controls and to examine the contribution of various factors to the increased disease severity experience by African-American SLE patients.


Condition
Systemic Lupus Erythematosus

MedlinePlus related topics:   Autoimmune Diseases    Lupus   

ChemIDplus related topics:   Silicon dioxide   

U.S. FDA Resources

Study Type:   Observational
Official Title:   Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus Study (CLU) and Disease Progression and Activity in the Carolina Lupus Study

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   640
Study Start Date:   December 1996
Estimated Study Completion Date:   March 2007

Detailed Description:

Systemic lupus erythematosus (SLE) is severe, chronic, disabling autoimmune disease that significantly affects health status and quality of life. Since the disease occurs most often in young to middle-aged adults, SLE can also affect work and disability. However, there is currently little information on work-related disability from longitudinal, population-based studies of SLE.

Disease damage will be assessed using the System Lupus international Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index, a standardized and validated instrument that is completed by the patient's physician.

This study will allow us to determine the feasibility of obtaining reliable data on disease damage from more than 50 physicians involved in the treatment of patients in the Carolina Lupus Study. This developmental work is a necessary foundation for any additional follow-up studies of the Carolina Lupus Study cohort. We will also be able to examine associations with disability in patients and in controls and to examine the contribution of various factors to the increased disease severity experience by African-American SLE patients.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria
  • INCLUSION CRITERIA:

Patients were eligible for the study if they met the 1997 revised American College of Rheumatology classification criteria for SLE (32, 33), were diagnosed between January 1, 1995 and July 31, 1999, were 18 years or older at study enrollment, had lived within the study area during at least 6 months of the year prior to diagnosis, and could speak and understand English.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00342095

Locations
United States, North Carolina
University of North Carolina    
      Chapel Hill, North Carolina, United States, 27599-7030
East Carolina University    
      Greenville, North Carolina, United States, 27858-4354
Duke University Medical Center    
      Durham, North Carolina, United States, 27710
Wake Medical Center    
      Raleigh, North Carolina, United States
NIEHS, Research Triangle Park    
      Research Triangle Park, North Carolina, United States, 27709
United States, South Carolina
Medical University of South Carolina    
      Columbia, South Carolina, United States, 29208

Sponsors and Collaborators
  More Information


Study ID Numbers:   999997002, OH97-E-N002
First Received:   June 19, 2006
Last Updated:   March 5, 2008
ClinicalTrials.gov Identifier:   NCT00342095
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Autoimmune Diseases  
Estrogen  
Silica  
Pesticides
Major Histocompatibility Complex
Genetic Susceptibility

Study placed in the following topic categories:
Autoimmune Diseases
Disease Susceptibility
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Disease Progression
Genetic Predisposition to Disease

Additional relevant MeSH terms:
Immune System Diseases

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers